Latest news with #QuestDiagnosticsIncorporated
Irish Examiner
25-06-2025
- Health
- Irish Examiner
Woman with terminal cervical cancer settles case against HSE and US laboratory
A 54-year-old woman who has terminal cervical cancer has settled a High Court action against the HSE and a US laboratory over the alleged misinterpretation of smear tests. The woman who cannot be identified by order of the court, the High Court heard, has incurable Stage Four cervical cancer. The action related to five smear tests taken between 2011 and 2018. Her counsel, Patrick Treacy SC instructed by Cian O'Carroll solicitors, told the court that the case had been resolved after mediation this week. The settlement against the HSE and the US laboratory Quest Diagnostics Incorporated with an address in New Jersey is without an admission of liability. The action had been case managed by the High Court because of the woman's diagnosis. Woman's claims In the proceedings, it was claimed as a result of alleged delay, the woman lost the opportunity of cure and her life expectancy has been severely impaired and her enjoyment of life has been catastrophically damaged. It was claimed her cancer had been allegedly allowed to develop and spread unidentified, unmonitored and untreated until she was ultimately diagnosed following her attendance at a hospital emergency department in late 2024. It was claimed that the woman had a smear test under the CervicalCheck screening programme in February 2011 and the report showed a lesion and a procedure was arranged with a follow smear arranged for six months later. She had another smear test in December 2011 which came back as negative and also in June 2012 which was also negative. At the end of December 2013, it was claimed the woman had another smear test and cells of uncertain significance were detected and a referral was made to a colposcopy clinic. A further smear test in October 2014 came back as negative and she also had a smear test in August 2018 which was returned as negative. She became unwell on holiday last year and on her return home she was referred for review where an MRI scan showed a cervical tumour and she began chemotherapy. It was claimed had any of the five smear tests been correctly reported, there would have been a different approach to her care and she would have been advised to undergo a hysterectomy. It was contended that on the balance of probabilities her high grade pre-cancer would have been cured and it would not have developed into advanced cancer lesion requiring intensive palliative chemotherapy. All of the claims were denied. Noting the settlement, Mr Justice Paul Coffey said he was delighted to hear the case had been resolved.
Malaysian Reserve
17-05-2025
- Business
- Malaysian Reserve
Quest Diagnostics to Speak at the William Blair 45th Annual Growth Stock Conference
SECAUCUS, N.J., May 16, 2025 /PRNewswire/ — Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during a presentation at the William Blair 45th Annual Growth Stock Conference in Chicago on Tuesday, June 3, 2025, at 11:00 a.m. Eastern Time. The presentation session will be webcast live during the conference on the company's investor relations page, which can be accessed at In addition, the archived webcast will be available within 24 hours after the conclusion of the live event and will remain available until July 3, 2025. About Quest DiagnosticsQuest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our more than 55,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives and create a healthier world.
Yahoo
03-04-2025
- Business
- Yahoo
Quest Diagnostics' (NYSE:DGX) Dividend Will Be Increased To $0.80
Quest Diagnostics Incorporated's (NYSE:DGX) dividend will be increasing from last year's payment of the same period to $0.80 on 21st of April. This takes the dividend yield to 1.9%, which shareholders will be pleased with. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. A big dividend yield for a few years doesn't mean much if it can't be sustained. Before making this announcement, Quest Diagnostics was easily earning enough to cover the dividend. This means that most of its earnings are being retained to grow the business. The next year is set to see EPS grow by 33.6%. If the dividend continues on this path, the payout ratio could be 32% by next year, which we think can be pretty sustainable going forward. Check out our latest analysis for Quest Diagnostics The company has been paying a dividend for a long time, and it has been quite stable which gives us confidence in the future dividend potential. Since 2015, the annual payment back then was $1.32, compared to the most recent full-year payment of $3.20. This works out to be a compound annual growth rate (CAGR) of approximately 9.3% a year over that time. The dividend has been growing very nicely for a number of years, and has given its shareholders some nice income in their portfolios. The company's investors will be pleased to have been receiving dividend income for some time. However, Quest Diagnostics has only grown its earnings per share at 4.6% per annum over the past five years. If Quest Diagnostics is struggling to find viable investments, it always has the option to increase its payout ratio to pay more to shareholders. Overall, a dividend increase is always good, and we think that Quest Diagnostics is a strong income stock thanks to its track record and growing earnings. Earnings are easily covering distributions, and the company is generating plenty of cash. All of these factors considered, we think this has solid potential as a dividend stock. Market movements attest to how highly valued a consistent dividend policy is compared to one which is more unpredictable. However, there are other things to consider for investors when analysing stock performance. For example, we've picked out 1 warning sign for Quest Diagnostics that investors should know about before committing capital to this stock. Looking for more high-yielding dividend ideas? Try our collection of strong dividend payers. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
23-03-2025
- Business
- Yahoo
Quest Diagnostics (DGX) and Google Cloud to Transform Healthcare Data with AI
We recently compiled a list of the Top 8 AI News Updates Investors Shouldn't Miss. In this article, we are going to take a look at where Quest Diagnostics Incorporated (NYSE:DGX) stands against the other AI stocks. On March 19th, the stock market bounced back after the US Federal Reserve kept interest rates unchanged at 4.25% to 4.5%. The Fed also anticipated two rate cuts this year despite elevated inflation. The S&P 500 index was up over 1%, while the Nasdaq Composite jumped by well over 200 points. The rally was led by the magnificent seven stocks after weeks of market declines amid trade wars and disappointing economic data. Elsewhere, AI continues to transform industries and individual lives, from AI nurses reshaping hospital care to schools reporting that students are learning faster and more effectively with AI. Furthermore, AngelList CEO Avlok Kohli claimed that all software companies are AI companies now. 'The enthusiasm into AI actually carries over into everything, which effectively impacts all startups,' said Kohli when asked if investors are as excited about emerging startups outside of AI. Meanwhile, security risks surrounding AI continue to loom. Computer scientist and AI pioneer Fei-Fei Li co-authored a report suggesting that lawmakers should consider AI risks that 'have not yet been observed in the world' when devising AI regulations. The report highlighted that the novel risks posed by AI could require legislation that compels AI developers to publicly report their safety tests and security protocols. We selected AI stocks by reviewing news articles, stock analysis, and press releases. We listed the stocks in ascending order of their hedge fund sentiment taken from Insider Monkey's Q4 2024 database of over 1000 hedge funds. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). A healthcare specialist providing a risk assessment for a patient. Quest Diagnostics Incorporated (NYSE:DGX) leverages technology and innovation to offer diagnostic testing and information services. It uses large repositories of de-identifiable clinical lab results to help physicians gain accurate insights into diseases for better treatment and patient outcomes. The company has ramped up the deployment of AI in several areas of its organization, including microbiology and cytology testing, specimen processing, and customer service. On March 18th, Quest Diagnostics (NYSE:DGX) announced a partnership with Google Cloud to optimize data management, enhance data analytics, improve patient engagement, and personalize experiences for providers. The company will utilize Google Cloud's GenAI and data analytics technologies across segments, including R&D, operations, administrative workflows, and customer experience, while ensuring data privacy. "We are excited about the potential to innovate and personalize the services we bring to our patients, clients, and employees. Google Cloud provides a best-in-class platform for securely streamlining and integrating data to generate novel insights and improve productivity. Google Cloud's generative AI capabilities can help dismantle care roadblocks by personalizing the way patients and providers interact with us, improving care access, customer experiences, and quality." Overall, DGX ranks 3rd on our list of top AI news updates investors shouldn't miss. While we acknowledge the potential of DGX as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than DGX but that trades at less than 5 times its earnings, check out our report about the . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at .
Yahoo
27-02-2025
- Business
- Yahoo
Quest Diagnostics (NYSE:DGX) Has Announced That It Will Be Increasing Its Dividend To $0.80
Quest Diagnostics Incorporated (NYSE:DGX) will increase its dividend from last year's comparable payment on the 21st of April to $0.80. Based on this payment, the dividend yield for the company will be 1.8%, which is fairly typical for the industry. Check out our latest analysis for Quest Diagnostics We like a dividend to be consistent over the long term, so checking whether it is sustainable is important. However, Quest Diagnostics' earnings easily cover the dividend. This means that most of its earnings are being retained to grow the business. The next year is set to see EPS grow by 34.6%. If the dividend continues along recent trends, we estimate the payout ratio will be 31%, which is in the range that makes us comfortable with the sustainability of the dividend. The company has a sustained record of paying dividends with very little fluctuation. Since 2015, the annual payment back then was $1.32, compared to the most recent full-year payment of $3.20. This means that it has been growing its distributions at 9.3% per annum over that time. Dividends have grown at a reasonable rate over this period, and without any major cuts in the payment over time, we think this is an attractive combination as it provides a nice boost to shareholder returns. Investors could be attracted to the stock based on the quality of its payment history. Earnings have grown at around 4.6% a year for the past five years, which isn't massive but still better than seeing them shrink. Earnings growth is slow, but on the plus side, the dividend payout ratio is low and dividends could grow faster than earnings, if the company decides to increase its payout ratio. Overall, we think this could be an attractive income stock, and it is only getting better by paying a higher dividend this year. Distributions are quite easily covered by earnings, which are also being converted to cash flows. Taking this all into consideration, this looks like it could be a good dividend opportunity. Investors generally tend to favour companies with a consistent, stable dividend policy as opposed to those operating an irregular one. Meanwhile, despite the importance of dividend payments, they are not the only factors our readers should know when assessing a company. Taking the debate a bit further, we've identified 1 warning sign for Quest Diagnostics that investors need to be conscious of moving forward. Is Quest Diagnostics not quite the opportunity you were looking for? Why not check out our selection of top dividend stocks. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
